JTE907 is a selective inverse-agonist of cannabinoid receptor 2 (CB2). It shows an antiedema effect in a carageenin-induced mouse paw model. Recently, it was used in a study to measure the effects of CB2 interactors with immune response to vaccines in mice. JTE907 enhanced immune response in a murine model.
| Cas No. | 282089-49-0 |
|---|---|
| Purity | ≥98% |
| Formula | C24H26N2O6 |
| Formula Wt. | 438.48 |
| Chemical Name | N-(1,3-benzodioxol-5-ylmethyl)-1,2-dihydro-7-methoxy-2-oxo-8-(pentyloxy)-3-Quinolinecarboxamide |
| IUPAC Name | N-(1,3-benzodioxol-5-ylmethyl)-7-methoxy-2-oxo-8-pentoxy-1H-quinoline-3-carboxamide |
| Synonym | JTE-907, JTE 907 |
| Solubility | Soluble in DMSO (100 mM), and ethanol (10 mM). |
| Appearance | White to off-white powder |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Dotsey E, Ushach I, Pone E et al. Transient Cannabinoid Receptor 2 Blockade during Immunization Heightens Intensity and Breadth of Antigen-specific Antibody Responses in Young and Aged mice. Sci Rep. 2017 Feb 17;7:42584. PMID: 28209996.
Iwamura H, Suzuki H, Ueda Y et al. In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor. J Pharmacol Exp Ther. 2001 Feb;296(2):420-5. PMID: 11160626.
